Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding.
Luca AntonelliPedro David Wendel-GarciaManja DeforthLuca AfferiCostantino LeonardoFrancesco EspertoMarco BorghesiAlessandro AntonelliKarl H TullyPaolo UmariSimone AlbisinniAndrea MariRenate PichlerFrancesco ClapsJeremy Yuen Chun TeohMathieu RoumiguiéGerald Bastian SchulzLuca OrecchiaShahrokh F ShariatMorgan RoupretGautier MarcqCedric PoyetMajed AlrumayyanMichael RinkStefania ZamboniMaria Riaza MontesSteven OkoyeRiccardo CampiWojciech KrajewskiLaura MertensMeftun CulpanLuke T LavalléeMarco MoschiniUlrike HeldChristian Daniel Fankhausernull nullPublished in: BJU international (2024)
In this retrospective analysis, the benefit of thromboprophylaxis during neoadjuvant chemotherapy before cystectomy is in line with data from randomised trials in other malignancies. Our data suggest thromboprophylaxis is protective against VTEs and should be the standard of care during neoadjuvant chemotherapy.
Keyphrases
- neoadjuvant chemotherapy
- venous thromboembolism
- locally advanced
- direct oral anticoagulants
- lymph node
- sentinel lymph node
- electronic health record
- clinical trial
- healthcare
- big data
- atrial fibrillation
- palliative care
- rectal cancer
- open label
- squamous cell carcinoma
- study protocol
- double blind
- radiation therapy
- chronic pain
- placebo controlled
- early stage
- deep learning
- robot assisted